<DOC>
	<DOCNO>NCT00844324</DOCNO>
	<brief_summary>This study design Phase-I , 2-period , cross-over , randomised , open-label , single centre study determine bioequivalence single 32 mg dose propose commercial oral suspension candesartan cilexetil ( 1 mg/mL ) single 32 mg dose candesartan cilexetil oral suspension ( 1.6 mg/mL ) use paediatric program .</brief_summary>
	<brief_title>Bioequivalence Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Body mass index ( BMI ) 1927 kg/m2 calculate height weight Screening visit Clinically normal physical finding include ECG safety laboratory value Screening visit Day 1 treatment period , include negative result drugsofabuse , alcohol , Hepatitis B , Hepatitis C HIV . History significant mental , cardiac , renal , hepatic significant gastrointestinal disease ( may affect rate extent absorption IP ) , judge Investigator Any condition could modify absorption IPs Previous randomisation treatment present study History symptom sign ongoing severe allergic disease/hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Candesartan</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>